Home Neuronal Signaling Adrenergic Receptor agonist Mirabegron

research use only

Mirabegron Adrenergic Receptor agonist

Cat.No.S4009

Mirabegron (YM 178) is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM.
Mirabegron Adrenergic Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 396.51

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S400901 DMSO]79 mg/mL]false]Ethanol]8 mg/mL]false]Water]Insoluble]false Purity: 99.8%
99.8

Chemical Information, Storage & Stability

Molecular Weight 396.51 Formula

C21H24N4O2S

 Storage (From the date of receipt)
CAS No. 223673-61-8 Download SDF Storage of Stock Solutions

Synonyms YM 178 Smiles C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O

Solubility

In vitro
Batch:

DMSO : 79 mg/mL (199.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 8 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
β3-adrenoceptor [1]
22.4 nM(EC50)
In vitro
Mirabegron concentration-dependently increases the accumulation of cAMP in CHO cells expressing human 3-adrenoceptors (ARs) with I.A. of 0.8. This compound has little agonistic effect on 1- and 2-ARs. It concentration-dependently relaxes rat and Human bladder smooth muscle strips precontracted with 10-6 M or 10-7 M carbachol with EC50 values of 5.1 μM and 0.78 μM, respectively. The maximal relaxant effects of this chemical are 94.0 % and 89.4% that of carbachol, respectively. [1] It is a time-dependent inhibitor of CYP2D6 in the presence of NADPH as the IC50 value in human liver microsomes decreased from 13 to 4.3 μM after 30 min preincubation. This compound acts partly as an irreversible or quasi-irreversible metabolism-dependent inhibitor of CYP2D6. [2]
In vivo
Mirabegron produces a dose-dependent decrease in the frequency of rhythmic bladder contraction in anesthetized rats. 3 mg/kg i.v. this compound suppresses the frequency to 2 counts/10 min. It does not decrease the amplitude of rhythmic bladder contraction. [1] This chemical decreases primary bladder afferent activity and bladder microcontractions in rats. It (0.3 and 1 mg/kg) inhibits mechanosensitive single-unit afferent activities (SAAs) of Aδ fibers in response to bladder filling. SAAs of C-fibers decrease only at 1 mg/kg this compound treatment. Its administration suppresses the mean bladder pressure and the number of microcontractions during an isovolumetric condition of the bladder. [3] It is efficient on facilitation of bladder storage. This compound dose-dependently decreases the resting intravesical pressure. It dose dependently decreases the frequency of nonvoiding contractions, considered an index of abnormal response in bladder storage. It exhibits no significant effects on the amplitude of nonvoiding contractions, micturition pressure, threshold pressure, voided volume, residual volume, or bladder capacity. [4]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05621616 Recruiting
Neurogenic Detrusor Overactivity
Astellas Pharma Global Development Inc.|Astellas Pharma Inc
 February 28 2024 Phase 3
NCT05040984 Recruiting
Overactive Bladder Syndrome
Far Eastern Memorial Hospital
 April 30 2021 --
NCT04641975 Terminated
Overactive Bladder (OAB)|Pharmacokinetics of Mirabegron
Astellas Pharma Global Development Inc.|Astellas Pharma Inc
 March 15 2021 Phase 3
NCT04693897 Unknown status
Overactive Bladder Syndrome|Detrusor Overactivity
Chang Gung Memorial Hospital
 March 1 2021 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map